Bellevue Group AG Decreases Stock Holdings in Phreesia, Inc. $PHR

Bellevue Group AG lowered its holdings in Phreesia, Inc. (NYSE:PHR) by 11.7% in the 2nd quarter, Holdings Channel.com reports. The fund owned 332,016 shares of the company’s stock after selling 44,147 shares during the quarter. Bellevue Group AG’s holdings in Phreesia were worth $9,449,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC lifted its holdings in shares of Phreesia by 9,375.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after acquiring an additional 3,000 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Phreesia by 53.0% in the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company’s stock valued at $137,000 after purchasing an additional 1,825 shares during the period. Entropy Technologies LP acquired a new position in shares of Phreesia during the first quarter worth about $202,000. AlphaQuest LLC lifted its stake in shares of Phreesia by 294.8% during the first quarter. AlphaQuest LLC now owns 8,216 shares of the company’s stock worth $210,000 after purchasing an additional 6,135 shares in the last quarter. Finally, Virtus Advisers LLC purchased a new stake in shares of Phreesia in the first quarter worth about $235,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Stock Performance

Phreesia stock opened at $16.22 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.12. Phreesia, Inc. has a 12 month low of $15.41 and a 12 month high of $32.76. The company has a fifty day moving average price of $21.46 and a two-hundred day moving average price of $25.01. The company has a market cap of $977.84 million, a PE ratio of -162.17 and a beta of 0.64.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The company had revenue of $120.33 million for the quarter, compared to the consensus estimate of $119.98 million. During the same period last year, the firm posted ($0.25) EPS. The company’s revenue for the quarter was up 12.7% on a year-over-year basis. Research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PHR. Truist Financial set a $29.00 target price on Phreesia in a report on Wednesday. BMO Capital Markets began coverage on shares of Phreesia in a research report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price objective for the company. Barclays initiated coverage on shares of Phreesia in a research note on Monday. They set an “overweight” rating and a $26.00 price objective on the stock. Raymond James Financial set a $33.00 target price on shares of Phreesia and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, Robert W. Baird lowered their price target on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.13.

Insider Buying and Selling

In related news, General Counsel Allison C. Hoffman sold 3,133 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $72,936.24. Following the sale, the general counsel owned 139,037 shares of the company’s stock, valued at approximately $3,236,781.36. This trade represents a 2.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Evan Roberts sold 3,761 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $87,556.08. Following the transaction, the insider owned 726,837 shares of the company’s stock, valued at approximately $16,920,765.36. The trade was a 0.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 26,174 shares of company stock valued at $603,835 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.